Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Newron Pharmaceuticals SpA ( (CH:NWRN) ) has shared an announcement.
Newron Pharmaceuticals reported its financial and operational results for the first half of 2025, highlighting significant progress in its pivotal Phase III development program for Evenamide, a potential breakthrough treatment for schizophrenia. The company has initiated patient enrollment for its ENIGMA-TRS studies and secured licensing agreements in Asia, while also expanding its intellectual property protection for Evenamide. The recent publication of preclinical data supports Evenamide’s potential as a transformative therapy, offering a novel approach to treating schizophrenia symptoms. Financially, Newron showed improved revenues and reduced net loss, indicating a positive trajectory for stakeholders.
The most recent analyst rating on (CH:NWRN) stock is a Hold with a CHF8.50 price target. To see the full list of analyst forecasts on Newron Pharmaceuticals SpA stock, see the CH:NWRN Stock Forecast page.
More about Newron Pharmaceuticals SpA
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company based in Bresso, near Milan, Italy, focusing on developing novel therapies for central and peripheral nervous system disorders. Its lead drug candidate is Evenamide, a first-in-class glutamate modulator for treatment-resistant schizophrenia. Newron has licensing agreements with EA Pharma and Myung In Pharm for the development and marketing of Evenamide in Asia. Additionally, Newron’s Parkinson’s drug, Xadago® (Safinamide), is marketed in over 20 countries.
Average Trading Volume: 56,365
Technical Sentiment Signal: Strong Buy
Current Market Cap: CHF178.7M
See more insights into NWRN stock on TipRanks’ Stock Analysis page.